Navigating Weight Loss: How Much Overweight to Take Ozempic and Similar Medications

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no BMI threshold for Ozempic, because Ozempic is not a weight-management medication. Its FDA labeling lists three indications — improving glycemic control in adults with type 2 diabetes mellitus, reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. No BMI, weight or obesity criterion appears anywhere in them. The numbers people are searching for are real, but they live on different labels: the semaglutide and tirzepatide products that actually hold weight-management approvals.

What Ozempic's Label Actually Requires

Eligibility for Ozempic keys off a diagnosis, not a body measurement. Every one of its three indications begins with type 2 diabetes mellitus. A person with a BMI of 41 and no diabetes diagnosis does not meet the labeled indication; a person with a BMI of 24 and type 2 diabetes does. That is the opposite of how most readers assume the medication works, and it is the single most consequential misunderstanding in this whole category.

This matters beyond trivia. Insurance prior authorization criteria are written against the approved indication, which is why weight-loss requests for Ozempic are routinely denied while the same plan may cover a different semaglutide product for the same person. It also explains why a clinician who is comfortable prescribing semaglutide may still redirect you to a different brand: they are matching the product to the indication rather than to the molecule.

Where the BMI Numbers Actually Come From

The familiar thresholds trace back to the weight-management labeling. When the FDA first approved Wegovy, the original 2021 prescribing information stated that it was indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of "30 kg/m2 or greater (obesity)" or "27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition."

Those two numbers — 30 and 27 — are what circulate online, usually detached from the brand they belong to and reattached to whichever GLP-1 the reader has heard of. They were never Ozempic criteria. They came from a separate application, supported by separate obesity trials, for a separate product that happens to contain the same active ingredient.

Today's Weight-Management Labels Describe Categories, Not Cutoffs

The current labeling has moved on. The present-day Wegovy prescribing information states the indication in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. It also carries an indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and an indication for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.

Zepbound follows the same pattern. Its prescribing information describes adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition, plus a separate indication for moderate to severe obstructive sleep apnea in adults with obesity. Neither current label prints a numeric BMI in the indication statement. Eligibility now rests on the clinical categories themselves, which shifts the judgment toward the prescriber and away from a lookup table.

How "Overweight" and "Obesity" Are Defined

Because the labels lean on those two words, the definitions matter. The CDC's adult BMI categories are: underweight below 18.5, healthy weight from 18.5 to less than 25, overweight from 25 to less than 30, and obesity at 30 or greater. Obesity is subdivided into class 1 at 30 to less than 35, class 2 at 35 to less than 40, and class 3 — severe obesity — at 40 or greater.

BMI is calculated from height and weight alone. It does not measure body composition, fat distribution, muscle mass or metabolic health, and two people who land on the same number can have very different clinical pictures. That limitation is exactly why the current labels frame eligibility as a clinical category rather than as a threshold you either clear or you do not.

The Comorbid Condition Is Doing Half the Work

In the overweight range, the label does not treat body mass as sufficient on its own. It requires at least one weight-related comorbid condition alongside it. Two adults with identical BMIs of 28 can therefore sit on opposite sides of the labeled population depending on what else is in their chart.

The indication statement does not publish a closed list of qualifying conditions, and no article can tell you whether yours counts. That determination is made by a licensed clinician reviewing your diagnoses, your laboratory results and your medication history — which is the honest answer to "do I qualify," and the reason the question cannot be resolved by arithmetic.

Adolescents Are Evaluated Differently

Wegovy's weight-reduction indication extends to pediatric patients aged 12 years and older with obesity, and adolescent eligibility is assessed against growth-referenced percentiles rather than a fixed adult number. The supporting evidence comes from a randomized, double-blind, placebo-controlled trial published in The New England Journal of Medicine, which enrolled 201 adolescents aged 12 to under 18 with obesity, defined as a BMI in the 95th percentile or higher, or overweight at the 85th percentile or higher plus at least one weight-related coexisting condition.

Over 68 weeks, mean BMI changed by −16.1% with semaglutide 2.4 mg versus 0.6% with placebo, and 73% of the semaglutide group achieved weight loss of at least 5% compared with 18% on placebo. Gastrointestinal adverse events were more frequent with semaglutide, at 62% versus 42%. Those were trial conditions with trial monitoring, not a template for any individual adolescent.

Meeting the Definition Is Not the Same as Being a Candidate

Semaglutide products carry a boxed warning regarding thyroid C-cell tumors observed in rodents, and they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Body mass has nothing to do with either of those exclusions. Pregnancy, pancreatitis history, concurrent GLP-1 use and gastrointestinal conditions all enter the same assessment.

It is also worth separating the approved brands from compounded preparations. Wegovy, Ozempic, Zepbound and Mounjaro are the FDA-approved products in this space. Compounded semaglutide is not an FDA-approved finished product, is not reviewed by the FDA for safety, effectiveness or quality before marketing, and is prepared by a licensed pharmacy pursuant to a prescription written for an individual patient after a clinician has evaluated them.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much overweight do you have to be to take Ozempic?

There is no such threshold. Ozempic's FDA labeling indicates it for glycemic control in adults with type 2 diabetes mellitus, for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and for kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease. No BMI, weight or obesity criterion appears in those indications. Eligibility is based on a type 2 diabetes diagnosis, not on body mass.

What BMI qualifies for a weight-management GLP-1?

The original 2021 Wegovy label specified an initial BMI of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight-related comorbid condition. Current Wegovy and Zepbound labeling states the indication in terms of obesity, or overweight with at least one weight-related comorbid condition, without printing numeric cutoffs in the indication statement. The CDC defines adult overweight as a BMI of 25 to less than 30 and obesity as 30 or greater.

Does a BMI of 27 qualify on its own?

No. In the overweight range the labeling requires at least one weight-related comorbid condition alongside the body mass criterion. Two people with the same BMI of 27 or 28 can fall on opposite sides of the labeled population depending on what else appears in their medical history. Whether a particular condition qualifies is a clinical judgment made by a licensed prescriber reviewing your full record, not something a calculator can settle.

Can adolescents be treated with semaglutide for weight?

Wegovy's weight-reduction indication includes pediatric patients aged 12 years and older with obesity. The supporting trial published in The New England Journal of Medicine enrolled 201 adolescents aged 12 to under 18 and reported a mean BMI change of −16.1% with semaglutide 2.4 mg versus 0.6% with placebo over 68 weeks. Gastrointestinal adverse events occurred in 62% of the semaglutide group versus 42% on placebo.

If I meet the definition, will I be prescribed one?

Not automatically. Body mass is one input among several. Semaglutide products carry a boxed warning about thyroid C-cell tumors seen in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Pregnancy, pancreatitis history and concurrent GLP-1 use are also weighed. Only a licensed clinician who has evaluated you can make that determination.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.